Open AccessFecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children
Author(s) -
Davidovics Zev H.,
Michail Sonia,
Nicholson Maribeth R.,
Kociolek Larry K.,
Pai Nikhil,
Hansen Richard,
Schwerd Tobias,
Maspons Aldo,
Shamir Raanan,
Szajewska Hania,
Thapar Nikhil,
Meij Tim,
Mosca Alexis,
Vandenplas Yvan,
Kahn Stacy A.,
Kellermayer Richard
Publication year - 2019
Publication title -
journal of pediatric gastroenterology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 131
eISSN - 1536-4801
pISSN - 0277-2116
DOI - 10.1097/mpg.0000000000002205
Subject(s) - clostridium difficile , medicine , fecal bacteriotherapy , microbiome , disease , transplantation , feces , inflammatory bowel disease , ulcerative colitis , colitis , intensive care medicine , immunology , gastroenterology , bioinformatics , microbiology and biotechnology , antibiotics , biology
Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.